Table 2.
Summary of the clinical pharmacist effect on patients’ outcomes
| Authors | Therapeutic | Safety | Humanistic | Economic |
|---|---|---|---|---|
| Samtia 2013 [39] |
FBS* HBA1C* Waist Circumference* |
– | Compliance (+) | – |
| Khan et al. 2014 [47] | – | DRP | – | – |
| Kaukab et al. [40] | – | Depression (+) | – | |
| Saleem et al., 2015 [41] |
SBP (+) DBP (+) |
– |
Knowledge (+) Adherence (+) EQ 5D (−) EQ-VAS (+) |
– |
| Amer et al. 2018 [42] |
SBP (+) DBP (+) |
– |
Knowledge (+) Adherence (+) EQ 5D (+) EQ-VAS (+) |
– |
| Ali et al. 2019 [43] | SVR 12 (+) |
ADE (+) DDI (+) |
Adherence (+) | – |
| Javaid et al. 2019 [44] |
Waist* BMI (+) HbA1C (+) SBP (+) DBP (+) Cholesterol (+) Triglycerides (+) Serum creatinine (+) eGFR (+) |
ADE (+) DDI (+) |
Knowledge (+) | – |
| Chatha et al. 2020 [45] | CD4 Cell Count (+) | – | Adherence (+) | – |
| Khokhar et al. 2020 [46] |
CBC* RFT* Blood Glucose* Electrolytes* |
– |
Knowledge (+) Adherence (+) |
– |
*No significant (P > 0.05) difference between intervention and control group, + = significant (P < 0.05) effect in favor of intervention group, − = significant (P < 0.05) effect in favor of control group SVR 12 = sustained virological response at 12 weeks, FBS = Fasting blood sugar, ADE = adverse drug event, CBC=Complete Blood count, RFT = renal function test, BMI = Body mass index, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, eGFR = estimated glomerular filtration rate